HER-2neu Testing and Therapy in Gastroesophageal Adenocarcinoma

Abstract EN

Despite ongoing advances in the treatment of gastroesophageal cancer, prognosis remains poor.

The best promise to improve this poor survival is provided by new targeted agents.

Of these, human epidermal growth factor receptor 2 (HER2) is currently in the spotlight.

In this review, we provide an overview of recent developments in HER2 testing and results of clinical trials targeting HER2 in gastroesophageal adenocarcinoma.

Based on the encouraging ToGA trial findings it is now expected that routine HER2 testing will be included in the diagnostic work-up of patients with advanced gastric cancer.

With regard to this testing, overexpression of the HER2 protein seems to possess the best predictive properties.

However, HER2 immunohistochemistry (IHC) is subject to assay and interobserver variability, so standardization and internal and external proficiency testing is an absolute prerequisite, especially as the IHC scoring system in gastric cancer is different from that of breast cancer.

Further study is needed to investigate the clinical meaning of the significant heterogeneity observed in both gene amplification and protein overexpression in gastroesophageal cancer.

Highly effective therapies for gastroesophageal cancer can only be accomplished by a multi-targeted approach, considering crosstalk between pathways and continuing to optimize chemotherapy.